FMR LLC - 08 Dec 2025 Form 4 Insider Report for Structure Therapeutics Inc. (GPCR)

Role: Other*, 10%+ Owner
Signature: /s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Issuer symbol: GPCR
Transactions as of: 08 Dec 2025
Net transactions value: -$3,768,430
Form type: 4
Filing time: 10 Dec 2025, 14:07:23 UTC
Previous filing: 17 Nov 2025
Next filing: 20 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
FMR LLC	Other*, 10%+ Owner	245 SUMMER STREET, BOSTON	/s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson	10 Dec 2025	0000315066

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	GPCR	Ordinary Shares						36,909	08 Dec 2025	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
holding	GPCR	Ordinary Shares						434,298	08 Dec 2025	F-Prime Capital Partners Life Sciences Fund VI LP

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Ownership	Footnotes
transaction	GPCR	American Depositary Shares	Sale	$65,597	-709	-17%	$92.52^*	3,393	08 Dec 2025	Ordinary Shares	2,127	F-Prime Capital Partners Life Sciences Advisors Fund VI LP	F1, F2
transaction	GPCR	American Depositary Shares	Sale	$17,202	-183	-5.4%	$94.00^*	3,210	08 Dec 2025	Ordinary Shares	549	F-Prime Capital Partners Life Sciences Advisors Fund VI LP	F1, F3
transaction	GPCR	American Depositary Shares	Sale	$44,940	-475	-15%	$94.61^*	2,735	08 Dec 2025	Ordinary Shares	1,425	F-Prime Capital Partners Life Sciences Advisors Fund VI LP	F1, F4
transaction	GPCR	American Depositary Shares	Sale	$86,325	-1,414	-52%	$61.05	1,321	08 Dec 2025	Ordinary Shares	4,242	F-Prime Capital Partners Life Sciences Advisors Fund VI LP	F1, F5
transaction	GPCR	American Depositary Shares	Sale	$81,114	-1,320	-100%	$61.45	1	08 Dec 2025	Ordinary Shares	3,960	F-Prime Capital Partners Life Sciences Advisors Fund VI LP	F1, F6
transaction	GPCR	American Depositary Shares	Sale	$771,339	-8,337	-17%	$92.52^*	39,918	08 Dec 2025	Ordinary Shares	25,011	F-Prime Capital Partners Life Sciences Fund VI LP	F1, F2
transaction	GPCR	American Depositary Shares	Sale	$202,946	-2,159	-5.4%	$94.00^*	37,759	08 Dec 2025	Ordinary Shares	6,477	F-Prime Capital Partners Life Sciences Fund VI LP	F1, F3
transaction	GPCR	American Depositary Shares	Sale	$528,775	-5,589	-15%	$94.61^*	32,170	08 Dec 2025	Ordinary Shares	16,767	F-Prime Capital Partners Life Sciences Fund VI LP	F1, F4
transaction	GPCR	American Depositary Shares	Sale	$1,015,567	-16,635	-52%	$61.05	15,535	08 Dec 2025	Ordinary Shares	49,905	F-Prime Capital Partners Life Sciences Fund VI LP	F1, F5
transaction	GPCR	American Depositary Shares	Sale	$954,626	-15,535	-100%	$61.45	0	08 Dec 2025	Ordinary Shares	46,605	F-Prime Capital Partners Life Sciences Fund VI LP	F1, F6
holding	GPCR	American Depositary Shares						1,515,558	08 Dec 2025	Ordinary Shares	4,546,674	Shares held by persons and entities whose shares are subject to reporting by the undersigned	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.
F2	The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $92.29 to $92.93. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
F3	The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $93.27 to $94.26. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
F4	The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $94.28 to $94.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
F5	The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $60.32 to $61.31. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
F6	The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $61.32 to $61.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.